Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR: AZD5718 in proteinuric chronic kidney disease
jRCT2031200201Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of atuliflapon in chronic kidney disease (CKD) and diabetic glomerulosclerosis (4 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in urine albumin-to-creatinine ratio (UACR) at Week 20. Started Dec 2020; status: completed.
02
Drugs
atuliflapon
03
Conditions
chronic kidney disease (CKD)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCT2031200201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200201.